Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?

Current Opinion in Rheumatology

Volumn 26, Issue 3, 2014, Pages 292-298

  Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

antineutrophil cytoplasmic autoantibody associated vasculitis; cyclophosphamide; rituximab

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB; CD20 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ANCA ASSOCIATED VASCULITIS; CD4 LYMPHOCYTE COUNT; CHURG STRAUSS SYNDROME; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; MAINTENANCE THERAPY; NEUTROPENIA; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REMISSION; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; B LYMPHOCYTE; DRUG EFFECTS; IMMUNOLOGY; LYMPHOCYTE DEPLETION; PROCEDURES;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOCYTE DEPLETION; RECURRENCE; REMISSION INDUCTION;

EID: 84897549269     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000049     Document Type: Review

References (45)

1. Hoffman GS, Leavitt RY, Kerr GS, Fauci AS. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-498.
2. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013; 65:1-11.
3. Schönermarck U, Gross WL, de Groot K. Treatment of ANCA-associated vasculitis. Nat Rev Nephrol 2014; 10:25-36.
4. Rutgers A, Kallenberg CG. Refractory disease in antineutrophil cytoplasmic antibodies associated vasculitis. Curr Opin Rheumatol 2012; 24:245-251.
5. Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 2010; 62:1166-1173.
6. Hoffman GS. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis? Presse Med 2013; 42:643-650.
7. Furuta S, Jayne D. Emerging therapies in antineutrophil cytoplasmic antibodyassociated vasculitis. Curr Opin Rheumatol 2014; 26:1-16.
8. Furuta S, Jayne DR. Antineutrophil cytoplasm antibody-associated vasculitis: recent developments. Kidney Int 2013; 84:244-249.
9. Kallenberg CG. Renal vasculitis in 2012: reclassification and the introduction of biological. Nat Rev Nephrol 2013; 9:70-72.
10. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363:221-232.
11. Jones RB, Cohen Tervaert JW, Hauser Th, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-220.
12. Miloslavsky EM, Specks U, Merkel PA, et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2013; 65:2441-2449.
13. Specks U, Merkel PA, Seo Ph, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med 2013; 369:417-427.
14. Berden AE, Jones RB, Erasmus DD, et al. Tubular lesions predict renal outcome in antineutrophil cytoplasmic antibody-associated glomerulonephritis after rituximab therapy. J Am Soc Nephrol 2012; 23:313-321.
15. de Lind van Wijngaarden RA, Hauer HA, Wolterbeek R, et al. European Vasculitis Study Groep (EUVAS): clinical and histologic determinants of renal outcome in ANCA-associated vasculitis: a prospective analysis of 100 patients with severe renal involvement. J Am Soc Nephrol 2006; 17:2264-2274.
16. Murakami C, Manoharan P, Carter-Monroe N, Gutha D. Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis post kidney transplant. Transpl Int 2013; 26:1225-1231.
17. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis 2007; 66:605-617.
18. Mukhtyar C, Guillevin L, Cid M, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 2009; 68:310-317.
19. Keogh KA, Wylan ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262-268.
20. Keogh KA, Ytterberg SR, Fervenza FC, et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173:180-187.
21. Seo P, Specks U, Keogh KA. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J Rheumatol 2008; 35:2017-2023.
22. Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2156-2168.
23. Cartin-Ceba R, Golbin JM, Keogh KA, et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012; 64:3770-3778.
24. Holle JU, Dubrau C, Herlyn K, et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2013; 71: 327-333.
25. Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65:853-858.
26. Taylor SR, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis. Arthritis Rheum 2009; 60:1540-1547.
27. Joshi L, Lightman SL, Salama AD, et al. Rituximab in refractory ophthalmic Wegener's granulomatosis: PR3 titers may predict relapse, but repeat treatment can be effective. Ophthalmology 2011; 118:2498-2503.
28. Baslund B, Wiencke AK, Rasmussen N, et al. Treatment of orbital inflammation with rituximab in Wegener's granulomatosis. Clin Exp Rheumatol 2012; 30 (1 Suppl 70):S7-S10.
29. Patel AM, Lehman TJ. Rituximab for severe refractory pediatric Wegener's granulomatosis. J Clin Rheumatol 2008; 14:278-280.
30. Brunner J, Freund M, Prelog M, et al. Successful treatment of severe juvenile microscopic polyangiitis with rituximab. Clin Rheumatol 2009; 28:997-999.
31. Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011; 26:2865-2871.
32. Thiel J, Hässler F, Salzer U, et al. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther 2013; 15:R133.
33. Luqmani R. Maintenance of clinical remission in ANCA-associated vasculitis. Nat Rev Rheumatol 2013; 9:127-132.
34. Rhee EP, Laliberte KA, Niles JL. Rituximab as maintenance therapy for antineutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5:1394-1400.
35. Roubaud-Baudron C, Pagnoux C, Méaux-Ruault N, et al. Rituximab maintenance therapy for granulomatosis with polyangiitis and microscopic polyangiitis. J Rheumatol 2012; 39:125-130.
36. Charles P, Néel A, Tieulié N, et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicenter retrospective study on 80 patients. Rheumatol 2013; 53:532-539.
37. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis: a prospective study in 117 patients. Presse Med 2013; 42:679.
38. Besada E, Koldingsnes W, Nossent JC. Long-term efficacy and safety of preemptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single center. Rheumatol 2013; 52:2041-2047.
39. Besada E, Nossent JC. Should Pneumocystis jiroveci prophylaxis be recommended with rituximab treatment in ANCA-associated vasculitis? Clin Rheumatol 2013; 32:1677-1681.
40. Besada E, Koldingnes W, Nossent J. Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center. QJM 2012; 105:545-550.
41. Hugle B, Solomon M, Harvey E, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res (Hoboken) 2010; 62:1661-1664.
42. van Assen S, Agman-Levin N, Elkayam O, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011; 70:414-422.
43. Molley ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 2012; 64:3043-3051.
44. Guerry MJ, Brogan P, Bruce IN, et al. Recommendations for the use of rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Rheumatol 2012; 51:634-643.
45. Charles P, Bienvenu B, Bonnotte B, et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitis. Presse Med 2013; 42:1217-1230.